MB and chronic kidney disease: From a molecular mechanism perspective, subclinical elevations in serum Mb have recently been observed in DM and chronic kidney disease (CKD)16, which may be explained by diabetic muscle damage and abnormal glucose and lipid metabolism, suggesting that MetS components may be contributing to elevated serum Mb levels17–20.